Final NICE nod for Sanofi’s Gaucher therapy
Sanofi’s Cerdelga can now be funded on the NHS in England and Wales to treat type 1 Gaucher disease, after cost regulators issued final guidance backing ‘routine’ use of the therapy.
Read More
Tag: Gaucher disease
NICE u-turn backs Sanofi’s Gaucher disease drug
It is now looking likely that Sanofi’s Cerdelga will be funded on the NHS in England and Wales to treat type 1 Gaucher disease, after a u-turn by cost regulators.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
